Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이경은 | * |
dc.date.accessioned | 2021-08-05T16:31:05Z | - |
dc.date.available | 2021-08-05T16:31:05Z | - |
dc.date.issued | 2021 | * |
dc.identifier.issn | 1598-2998 | * |
dc.identifier.issn | 2005-9256 | * |
dc.identifier.other | OAK-29690 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/258460 | - |
dc.description.abstract | Purpose This study was conducted to determine the effectiveness of immune checkpoint inhibitors (ICIs) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum-containing chemotherapy. We also identified clinical biomarkers which may be predictive of patient prognosis. Materials and Methods We analyzed 125 patients with R/M HNSCC who received ICIs, retrospectively. Overall response rate (ORR) was the primary study outcome. Overall survival (OS) and progression-free survival (PFS) were the secondary study outcomes. Results The patients received anti & ndash;programmed cell death protein-1 (PD-1) (n=73, 58%), anti & ndash;programmed death-ligand 1 (PD-L1) (n=24, 19%), or a combination of anti & ndash;PD-1/PD-L1 and anti & ndash;cytotoxic T-lymphocyte antigen 4 (n=28, 22%). The median age was 57 years (range, 37 to 87). The location of the primary tumor was in the oral cavity in 28% of the cases, followed by oropharynx (27%), hypopharynx (20%), and larynx (12%). The ORR was 15% (19/125). With 12.3 months of median follow-up, median PFS was 2.7 months. Median OS was 10.8 months. A neutrophil-to-lymphocyte ratio (NLR) > 4 was significantly associated with poor response to ICIs (odds ratio, 0.30; p=0.022). A sum of the target lesions > 40 mm (hazard ratio [HR], 1.53; p=0.046] and a NLR > 4 (HR, 1.75; p=0.009) were considered to be predictive markers of short PFS. A poor performance status (HR, 4.79; p < 0.001), a sum of target lesions > 40 mm (HR, 1.93; p=0.025), and an NLR > 4 (HR, 3.36; p < 0.001) were the significant predictors for poor survival. Conclusion ICIs exhibited favorable antitumor activity in R/M HNSCC. Clinically, our findings can be used to recognize patients benefit from receiving ICI. | * |
dc.language | English | * |
dc.publisher | KOREAN CANCER ASSOCIATION | * |
dc.subject | Head and neck neoplasms | * |
dc.subject | Biomarkers | * |
dc.subject | Immune check point | * |
dc.subject | Platinum refractory | * |
dc.subject | Sum of target lesions | * |
dc.title | Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12 | * |
dc.type | Article | * |
dc.relation.issue | 3 | * |
dc.relation.volume | 53 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.startpage | 671 | * |
dc.relation.lastpage | 677 | * |
dc.relation.journaltitle | CANCER RESEARCH AND TREATMENT | * |
dc.identifier.doi | 10.4143/crt.2020.824 | * |
dc.identifier.wosid | WOS:000674117200008 | * |
dc.author.google | Lee, Yun-Gyoo | * |
dc.author.google | Chang, Hyun | * |
dc.author.google | Keam, Bhumsuk | * |
dc.author.google | Chun, Sang Hoon | * |
dc.author.google | Park, Jihyun | * |
dc.author.google | Park, Keon Uk | * |
dc.author.google | Shin, Seong Hoon | * |
dc.author.google | An, Ho Jung | * |
dc.author.google | Lee, Kyoung Eun | * |
dc.author.google | Lee, Keun-Wook | * |
dc.author.google | Kim, Hye Ryun | * |
dc.author.google | Kim, Sung-Bae | * |
dc.author.google | Ahn, Myung-Ju | * |
dc.author.google | Hwang, In Gyu | * |
dc.contributor.scopusid | 이경은(7501517217;58364338700) | * |
dc.date.modifydate | 20240123091958 | * |